Balchem Corporation Reports Third Quarter 2024 Financial Results
Balchem (NASDAQ: BCPC) reported strong third quarter 2024 financial results with net sales of $239.9 million, up 4.3% year-over-year. The company achieved record earnings from operations and adjusted EBITDA of $64.4 million, a 7.6% increase. Net earnings rose 16.4% to $33.8 million, with earnings per share of $1.03. The Human Nutrition and Health segment showed excellent performance with 5.4% sales growth, while Specialty Products grew 10.6%. Cash flows from operations were $51.3 million, with quarterly free cash flow of $42.2 million. The company's net debt decreased to $153.3 million with a leverage ratio of 0.6 times.
Balchem (NASDAQ: BCPC) ha riportato forti risultati finanziari per il terzo trimestre del 2024, con vendite nette di 239,9 milioni di dollari, in aumento del 4,3% rispetto all'anno precedente. L'azienda ha raggiunto guadagni record dalle operazioni e un EBITDA rettificato di 64,4 milioni di dollari, con un incremento del 7,6%. I guadagni netti sono aumentati del 16,4% a 33,8 milioni di dollari, con un utile per azione di 1,03 dollari. Il segmento Nutrizione Umana e Salute ha mostrato eccellenti performance con una crescita delle vendite del 5,4%, mentre i Prodotti Speciali sono cresciuti del 10,6%. I flussi di cassa dalle operazioni sono stati di 51,3 milioni di dollari, con un flusso di cassa libero trimestrale di 42,2 milioni di dollari. Il debito netto dell'azienda è diminuito a 153,3 milioni di dollari, con un rapporto di leva di 0,6 volte.
Balchem (NASDAQ: BCPC) reportó sólidos resultados financieros para el tercer trimestre de 2024, con ventas netas de 239.9 millones de dólares, un aumento del 4.3% en comparación con el año anterior. La compañía logró ganancias récord de las operaciones y un EBITDA ajustado de 64.4 millones de dólares, un incremento del 7.6%. Las ganancias netas aumentaron un 16.4% a 33.8 millones de dólares, con ganancias por acción de 1.03 dólares. El segmento de Nutrición Humana y Salud mostró un excelente desempeño con un crecimiento en ventas del 5.4%, mientras que los Productos Especiales crecieron un 10.6%. Los flujos de efectivo de las operaciones fueron de 51.3 millones de dólares, con un flujo de efectivo libre trimestral de 42.2 millones de dólares. La deuda neta de la compañía se redujo a 153.3 millones de dólares, con un índice de apalancamiento de 0.6 veces.
발켐 (NASDAQ: BCPC)는 2024년 3분기 강력한 재무 실적을 보고했으며, 순매출 2억 3,990만 달러로 전년 대비 4.3% 증가했습니다. 회사는 운영 수익에서의 기록적인 수익을 달성하였고, 조정 EBITDA는 6,440만 달러로 7.6% 증가했습니다. 순익은 16.4% 증가하여 3,380만 달러에 도달하였으며, 주당 순이익은 1.03달러입니다. 인간 영양 및 건강 부문은 5.4% 매출 성장으로 우수한 성과를 보였으며, 특수 제품은 10.6% 성장했습니다. 운영으로 인한 현금 흐름은 5,130만 달러였고, 분기 자유 현금 흐름은 4,220만 달러였습니다. 회사의 순부채는 1억 5,330만 달러로 감소하였고, 레버리지 비율은 0.6배입니다.
Balchem (NASDAQ: BCPC) a annoncé de solides résultats financiers pour le troisième trimestre 2024 avec des ventes nettes de 239,9 millions de dollars, en hausse de 4,3 % par rapport à l'année précédente. L'entreprise a réalisé des bénéfices records provenant des opérations et un EBITDA ajusté de 64,4 millions de dollars, soit une augmentation de 7,6 %. Le bénéfice net a augmenté de 16,4 % pour atteindre 33,8 millions de dollars, avec un bénéfice par action de 1,03 dollar. Le segment Nutrition Humaine et Santé a montré une excellente performance avec une croissance des ventes de 5,4 %, tandis que les Produits Spéciaux ont augmenté de 10,6 %. Les flux de trésorerie provenant des opérations se sont élevés à 51,3 millions de dollars, avec un flux de trésorerie disponible trimestriel de 42,2 millions de dollars. La dette nette de l'entreprise a diminué à 153,3 millions de dollars, avec un ratio d'endettement de 0,6 fois.
Balchem (NASDAQ: BCPC) berichtete über starke finanzielle Ergebnisse im dritten Quartal 2024 mit Nettoverkaufszahlen von 239,9 Millionen USD, was einem Anstieg von 4,3 % im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte Rekordgewinne aus dem operativen Geschäft und einen bereinigten EBITDA von 64,4 Millionen USD, was einem Anstieg von 7,6 % entspricht. Der Nettogewinn stieg um 16,4 % auf 33,8 Millionen USD, mit einem Gewinn pro Aktie von 1,03 USD. Der Geschäftsbereich Humanernährung und Gesundheit zeigte eine hervorragende Leistung mit einem Verkaufswachstum von 5,4 %, während Spezialprodukte um 10,6 % wuchsen. Die Cashflows aus dem operativen Geschäft betrugen 51,3 Millionen USD, mit einem quartalsweisen freien Cashflow von 42,2 Millionen USD. Der Nettoschuldenbetrag des Unternehmens verringerte sich auf 153,3 Millionen USD, mit einem Verschuldungsgrad von 0,6.
- Net sales increased 4.3% to $239.9 million
- Adjusted EBITDA grew 7.6% to record $64.4 million
- Net earnings rose 16.4% to $33.8 million
- Human Nutrition and Health segment sales up 5.4%
- Specialty Products segment sales increased 10.6%
- Gross margin improved 230 basis points to 35.6%
- Net debt reduced to $153.3 million with low leverage ratio of 0.6x
- Animal Nutrition and Health segment sales declined 1.9%
- Operating expenses increased by $4.4 million
- Higher effective tax rate at 22.9% vs 20.3% prior year
Insights
The Q3 2024 results demonstrate robust financial performance with several notable highlights.
Particularly impressive is the gross margin expansion of 230 basis points to
Balchem's strategic product launches demonstrate strong market positioning and innovation focus. The introduction of K2Vital® Delta Fermented and VitaCholine® Pro-Flo in the Human Nutrition segment addresses growing demand for specialized vitamin formulations. The launch of AminoShure®-XL in Animal Nutrition shows commitment to sustainable dairy farming solutions.
The company's debt reduction of
MONTVALE, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal third quarter ended September 30, 2024. For the quarter, the Company reported net sales of
Ted Harris, Chairman, President and CEO of Balchem said, “We delivered strong third quarter financials with solid revenue growth and record earnings from operations and adjusted EBITDA. We continue to see excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth.”
Third Quarter 2024 Financial Highlights:
- Net sales were
$239.9 million , an increase of4.3% compared to the prior year quarter. - Adjusted EBITDA was a record
$64.4 million , an increase of7.6% from the prior year quarter. - GAAP net earnings were
$33.8 million , an increase of16.4% from the prior year quarter. - GAAP earnings per share of
$1.03 compared to$0.90 in the prior year quarter and record adjusted earnings per share(a) of$1.13 compared to$1.04 in the prior year quarter. - Cash flows from operations were
$51.3 million for the third quarter of 2024, with quarterly free cash flow(a) of$42.2 million . - Strong sales growth and earnings from operations in both our Human Nutrition and Health and Specialty Products segments.
Recent Highlights:
- Balchem’s Human Nutrition and Health segment continued to bring innovative new products to its minerals and nutrients portfolio with two new solutions, K2Vital® Delta Fermented and VitaCholine® Pro-Flo. K2Vital® Delta Fermented is a vitamin K2 from fermentation in a patented microencapsulated form, and VitaCholine® Pro-Flo is an enhanced formulation designed for inclusion in multivitamins.
- Balchem’s Animal Nutrition and Health segment launched a newly developed product, AminoShure®-XL, which is a next generation rumen protected precision release lysine solution designed to consistently, reliably, and economically meet the lysine amino acid dietary requirements of lactating dairy cattle. AminoShure®-XL offers leading performance when considering feed stability, lysine content, and bioavailability compared to other products in the market and is a great addition to the Animal Nutrition and Health segment’s portfolio of high performing encapsulated products focused on optimizing dairy cow productivity and sustainability.
- Strong cash flows in the third quarter enabled us to make repayments on our revolving debt of
$39.6 million , bringing our net debt to$153.3 million , with an overall leverage ratio on a net debt basis of 0.6 times.
Mr. Harris said, “I am excited about the recent product launches in both our Human and Animal Nutrition and Health segments which add to the previously announced launch of Optifolin+® earlier this year, as we continue to focus on bringing innovative solutions for the health and nutritional needs of the world.”
Mr. Harris continued, “I am very pleased with our year-to-date 2024 financial performance as well as the progress we continue to make on our strategic growth initiatives which will help fuel our longer term growth.”
| Results for Period Ended September 30, 2024 (unaudited) (Dollars in thousands, except per share data) | ||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net sales | $ | 239,940 | $ | 229,948 | $ | 713,680 | $ | 693,740 | ||||
| Gross margin | 85,361 | 76,544 | 249,869 | 227,063 | ||||||||
| Operating expenses | 37,369 | 32,930 | 114,404 | 106,205 | ||||||||
| Earnings from operations | 47,992 | 43,614 | 135,465 | 120,858 | ||||||||
| Interest and other expenses | 4,099 | 7,139 | 13,496 | 16,864 | ||||||||
| Earnings before income tax expense | 43,893 | 36,475 | 121,969 | 103,994 | ||||||||
| Income tax expense | 10,056 | 7,400 | 27,077 | 22,099 | ||||||||
| Net earnings | $ | 33,837 | $ | 29,075 | $ | 94,892 | $ | 81,895 | ||||
| Diluted net earnings per common share | $ | 1.03 | $ | 0.90 | $ | 2.90 | $ | 2.52 | ||||
| Adjusted EBITDA(a) | $ | 64,379 | $ | 59,807 | $ | 187,515 | $ | 175,481 | ||||
| Adjusted net earnings(a) | $ | 36,928 | $ | 33,795 | $ | 106,089 | $ | 98,817 | ||||
| Adjusted net earnings per common share(a) | $ | 1.13 | $ | 1.04 | $ | 3.25 | $ | 3.05 | ||||
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,783 | 32,476 | 32,686 | 32,440 | ||||||||
| (a) | See “Non-GAAP Financial Information” for a reconciliations of GAAP and non-GAAP financial measures. |
Financial Results for the Third Quarter of 2024:
The Human Nutrition and Health segment generated sales of
The Animal Nutrition and Health segment generated quarterly sales of
The Specialty Products segment generated quarterly sales of
Record quarterly consolidated gross margin of
Net interest expense was
Third quarter cash flows provided by operating activities were
Ted Harris said, “The Balchem team delivered another strong quarter, once again highlighting the resilience of our business model in what continues to be a challenging market environment. We remain confident in the long-term growth outlook for our company as we continue to focus on progressing our strategic growth initiatives over the course of the remainder of 2024 and beyond.”
Quarterly Conference Call
A quarterly conference call will be held on Friday, October 25, 2024, at 11:00 AM Eastern Time (ET) to review third quarter 2024 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay three hours after the conclusion of the call through end of day Friday, November 8, 2024. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID #13749359.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," “likely,” "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this release. Factors that might cause differences from the forward-looking statements include those referred to or identified in Balchem’s Annual Report on Form 10-K for the year ended December 31, 2023 and other factors that may be identified elsewhere in this release or in our other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
Selected Financial Data (unaudited)
($ in 000’s)
| Business Segment Net Sales: | Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Human Nutrition and Health | $ | 152,283 | $ | 144,455 | $ | 452,955 | $ | 412,777 | ||||||||
| Animal Nutrition and Health | 52,906 | 53,944 | 156,384 | 180,162 | ||||||||||||
| Specialty Products | 33,191 | 30,004 | 99,898 | 94,961 | ||||||||||||
| Other and Unallocated (b) | 1,560 | 1,545 | 4,443 | 5,840 | ||||||||||||
| Total | $ | 239,940 | $ | 229,948 | $ | 713,680 | $ | 693,740 | ||||||||
| Business Segment Earnings Before Income Taxes: | Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Human Nutrition and Health | $ | 35,578 | $ | 31,275 | $ | 102,202 | $ | 77,209 | ||||||||
| Animal Nutrition and Health | 3,529 | 5,070 | 8,282 | 22,230 | ||||||||||||
| Specialty Products | 10,516 | 8,740 | 29,943 | 25,984 | ||||||||||||
| Other and Unallocated (b) | (1,631 | ) | (1,471 | ) | (4,962 | ) | (4,565 | ) | ||||||||
| Interest and other expenses | (4,099 | ) | (7,139 | ) | (13,496 | ) | (16,864 | ) | ||||||||
| Total | $ | 43,893 | $ | 36,475 | $ | 121,969 | $ | 103,994 | ||||||||
| (b) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs of | ||||||||||||||||
| Selected Balance Sheet Items | ||||||
| (Dollars in thousands) | September 30, 2024 | December 31, 2023 | ||||
| (unaudited) | ||||||
| Cash and Cash Equivalents | $ | 73,694 | $ | 64,447 | ||
| Accounts Receivable, net | 120,537 | 125,284 | ||||
| Inventories | 118,510 | 109,521 | ||||
| Other Current Assets | 13,247 | 14,990 | ||||
| Total Current Assets | 325,988 | 314,242 | ||||
| Property, Plant and Equipment, net | 277,429 | 276,039 | ||||
| Goodwill | 781,109 | 778,907 | ||||
| Intangible Assets with Finite Lives, net | 177,525 | 191,212 | ||||
| Right of Use Assets | 17,330 | 19,864 | ||||
| Other Assets | 17,563 | 16,947 | ||||
| Total Non-current Assets | 1,270,956 | 1,282,969 | ||||
| Total Assets | $ | 1,596,944 | $ | 1,597,211 | ||
| Current Liabilities | $ | 109,439 | $ | 148,491 | ||
| Revolving Loan | 227,000 | 309,569 | ||||
| Deferred Income Taxes | 50,460 | 52,046 | ||||
| Other Long-Term Obligations | 32,819 | 33,121 | ||||
| Total Liabilities | 419,718 | 543,227 | ||||
| Stockholders' Equity | 1,177,226 | 1,053,984 | ||||
| Total Liabilities and Stockholders' Equity | $ | 1,596,944 | $ | 1,597,211 | ||
| Balchem Corporation Condensed Consolidated Statements of Cash Flows (Dollars in thousands) | ||||||||
| (unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 94,892 | $ | 81,895 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 37,077 | 40,878 | ||||||
| Stock compensation expense | 12,787 | 12,267 | ||||||
| Other adjustments | (1,022 | ) | (6,241 | ) | ||||
| Changes in assets and liabilities | (14,052 | ) | (12,444 | ) | ||||
| Net cash provided by operating activities | 129,682 | 116,355 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures and intangible assets acquired | (22,936 | ) | (26,177 | ) | ||||
| Cash paid for acquisitions, net of cash acquired | — | (1,252 | ) | |||||
| Proceeds from the sale of assets | 272 | 1,881 | ||||||
| Proceeds from settlement of net investment hedge | — | 2,740 | ||||||
| Investment in affiliates | (113 | ) | (140 | ) | ||||
| Net cash used in investing activities | (22,777 | ) | (22,948 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from revolving loan | 26,000 | 18,000 | ||||||
| Principal payments on revolving loan | (108,569 | ) | (78,000 | ) | ||||
| Principal payments on finance lease | (169 | ) | (166 | ) | ||||
| Proceeds from stock options exercised | 15,084 | 3,888 | ||||||
| Dividends paid | (25,572 | ) | (22,872 | ) | ||||
| Purchase of common stock | (5,376 | ) | (4,025 | ) | ||||
| Net cash used in financing activities | (98,602 | ) | (83,175 | ) | ||||
| Effect of exchange rate changes on cash | 944 | 160 | ||||||
| Increase in cash and cash equivalents | 9,247 | 10,392 | ||||||
| Cash and cash equivalents, beginning of period | 64,447 | 66,560 | ||||||
| Cash and cash equivalents, end of period | $ | 73,694 | $ | 76,952 | ||||
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Table 1
(unaudited)
| Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Reconciliation of adjusted gross margin | ||||||||||||||||
| GAAP gross margin | $ | 85,361 | $ | 76,544 | $ | 249,869 | $ | 227,063 | ||||||||
| Inventory valuation adjustment (1) | — | — | — | 1,419 | ||||||||||||
| Amortization of intangible assets and finance lease (2) | 693 | 675 | 2,104 | 2,018 | ||||||||||||
| Restructuring costs (3) | — | 295 | — | 415 | ||||||||||||
| Adjusted gross margin | $ | 86,054 | $ | 77,514 | $ | 251,973 | $ | 230,915 | ||||||||
| Reconciliation of adjusted earnings from operations | ||||||||||||||||
| GAAP earnings from operations | $ | 47,992 | $ | 43,614 | $ | 135,465 | $ | 120,858 | ||||||||
| Inventory valuation adjustment (1) | — | — | — | 1,419 | ||||||||||||
| Amortization of intangible assets and finance lease (2) | 3,854 | 7,008 | 15,559 | 21,310 | ||||||||||||
| Restructuring costs (3) | 521 | 1,913 | 521 | 8,179 | ||||||||||||
| Transaction and integration costs (4) | 223 | (3,116 | ) | 704 | (8,300 | ) | ||||||||||
| Impairment charge (5) | 255 | — | 255 | — | ||||||||||||
| Nonqualified deferred compensation plan expense (6) | 406 | (86 | ) | 922 | 395 | |||||||||||
| Adjusted earnings from operations | $ | 53,251 | $ | 49,333 | $ | 153,426 | $ | 143,861 | ||||||||
| Reconciliation of adjusted net earnings | ||||||||||||||||
| GAAP net earnings | $ | 33,837 | $ | 29,075 | $ | 94,892 | $ | 81,895 | ||||||||
| Inventory valuation adjustment (1) | — | — | — | 1,419 | ||||||||||||
| Amortization of intangible assets and finance lease (2) | 3,926 | 7,080 | 15,775 | 21,526 | ||||||||||||
| Restructuring costs (3) | 521 | 1,913 | 521 | 8,179 | ||||||||||||
| Transaction and integration costs (4) | 223 | (3,116 | ) | 704 | (8,300 | ) | ||||||||||
| Impairment charge (5) | 255 | — | 255 | — | ||||||||||||
| Income tax adjustment (7) | (1,834 | ) | (1,157 | ) | (6,058 | ) | (5,902 | ) | ||||||||
| Adjusted net earnings | $ | 36,928 | $ | 33,795 | $ | 106,089 | $ | 98,817 | ||||||||
| Adjusted net earnings per common share - diluted | $ | 1.13 | $ | 1.04 | $ | 3.25 | $ | 3.05 | ||||||||
Table 2
(unaudited)
| Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands) | ||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| Net earnings - as reported | $ | 33,837 | $ | 29,075 | $ | 94,892 | $ | 81,895 | ||||||
| Add back: | ||||||||||||||
| Provision for income taxes | 10,056 | 7,400 | 27,077 | 22,099 | ||||||||||
| Interest and other expenses | 4,099 | 7,139 | 13,496 | 16,864 | ||||||||||
| Depreciation and amortization | 10,831 | 13,733 | 36,861 | 40,663 | ||||||||||
| EBITDA | 58,823 | 57,347 | 172,326 | 161,521 | ||||||||||
| Add back: | ||||||||||||||
| Non-cash compensation expense related to equity awards | 4,151 | 3,749 | 12,787 | 12,267 | ||||||||||
| Inventory valuation adjustment (1) | — | — | — | 1,419 | ||||||||||
| Restructuring costs (3) | 521 | 1,913 | 521 | 8,179 | ||||||||||
| Transaction and integration costs (4) | 223 | (3,116 | ) | 704 | (8,300 | ) | ||||||||
| Impairment charge (5) | 255 | — | 255 | — | ||||||||||
| Nonqualified deferred compensation plan expense (6) | 406 | (86 | ) | 922 | 395 | |||||||||
| Adjusted EBITDA | $ | 64,379 | $ | 59,807 | $ | 187,515 | $ | 175,481 | ||||||
Table 3
(unaudited)
| Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands) | ||||||||||||
| Three Months Ended September 30, | ||||||||||||
| 2024 | Effective Tax Rate | 2023 | Effective Tax Rate | |||||||||
| GAAP Income Tax Expense | $ | 10,056 | 22.9 | % | $ | 7,400 | 20.3 | % | ||||
| Impact of ASU 2016-09 (8) | 625 | 19 | ||||||||||
| Adjusted Income Tax Expense | $ | 10,681 | 24.3 | % | $ | 7,419 | 20.3 | % | ||||
| Nine Months Ended September 30, | ||||||||||||
| 2024 | Effective Tax Rate | 2023 | Effective Tax Rate | |||||||||
| GAAP Income Tax Expense | $ | 27,077 | 22.2 | % | $ | 22,099 | 21.3 | % | ||||
| Impact of ASU 2016-09 (8) | 1,952 | 863 | ||||||||||
| Adjusted Income Tax Expense | $ | 29,029 | 23.8 | % | $ | 22,962 | 22.1 | % | ||||
Table 4
(unaudited)
| Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Dollars in thousands) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net cash provided by operating activities | $ | 51,302 | $ | 46,526 | $ | 129,682 | $ | 116,355 | ||||||||
| Capital expenditures, proceeds from the sale of assets, and settlement of net investment hedge | (9,065 | ) | (8,320 | ) | (22,240 | ) | (21,212 | ) | ||||||||
| Free cash flow | $ | 42,237 | $ | 38,206 | $ | 107,442 | $ | 95,143 | ||||||||
| (1) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company's cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business. |
| (2) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. |
| (3) Restructuring costs: Expenses related to a reorganization of the business. The restructuring costs are included in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because they are inconsistent in amounts and frequency causing comparison of current and historical financial results to be difficult. |
| (4) Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (5) Impairment charge: An asset impairment charge in 2024 was related to the write off of an equity method investment. The impairment charge is included in our GAAP financial statements. Management excludes this item for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding this item from our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (6) Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. Adjustments have been made to the prior period presentation to conform with the current period presentation. |
| (7) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. |
| (8) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and nine months ended September 30, 2024 and 2023, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating Adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
FAQ
What was Balchem's (BCPC) revenue growth in Q3 2024?
What was Balchem's (BCPC) earnings per share in Q3 2024?
How much did Balchem's (BCPC) Human Nutrition segment grow in Q3 2024?
What was Balchem's (BCPC) adjusted EBITDA in Q3 2024?
